Skip to main content
. Author manuscript; available in PMC: 2009 Sep 30.
Published in final edited form as: J Infect Dis. 2009 Sep 15;200(6):955–964. doi: 10.1086/605126

Table 1.

Relationships between genetic polymorphisms and efavirenz plasma concentrations.

SNP LD with
516G→Ta
(r2)		 LD with
rs36118214a
(r2)		 Efavirenz (ng/mL),
median (IQR)		 n Efavirenz (ng/mL),
median (IQR)		 n Efavirenz (ng/mL),
median (IQR)		 n rhob P-
VALUE
CYP2A6
 rs28399433 0.124 0.02 GG - 0 GT 6073 [4170–7993] 7 TT 3066 [2307–5714] 38 −0.3494 0.0187
CYP2B6
 rs8109818 0.266 0.443 AA 4170 [3294–7738] 21 AG 2963 [1772–4779] 20 GG 2725 [1893–3379] 4 −0.4218 0.0039
 rs8105382 0.32 0.115 CC 2435 [1762–2813] 3 CT 3041 [2307–4067] 21 TT 4170 [3092–7681] 21 0.3578 0.0158
 rs11083595 0.786 0.183 CC 8228 [6715–14829] 6 CG 3652 [3034–6473] 27 GG 2345 [1402–2691] 12 −0.6041 <0.0001d
 rs892216 0.71 0.276 CC 1762 [1327–2435] 11 CT 3652 [3034–6473] 27 TT 7738 [3092–14829] 7 0.6065 <0.0001d
 rs12721652 0.372 0.24 CC 3911 [3063–7709] 20 CT 3218 [2440–6016] 20 TT 1762 [1326–2435] 5 −0.3917 0.0078
 rs2054675 0.831 0.194 CC 8718 [6715–14829] 7 CT 3533 [3034–6073] 26 TT 2345 [1402–2691] 12 −0.6338 <0.0001d
 rs28739581 0.38 0.257 AA 1762 [1327–2435] 5 AT 3294 [2497–6473] 19 TT 3911 [3063–7709] 20 0.3807 0.0108
 rs7250873 0.656 0.086 AA 2409 [1762–2813] 10 AG 3652 [2891–6073] 25 GG 7227 [3034–13528] 10 0.4389 0.0026
 rs3786547 0.831 0.194 CC 8718 [6715–14829] 7 CT 3533 [3034–6073] 26 TT 2345 [1402–2691] 12 −0.6338 <0.0001d
 rs35490259 0.174 0.5 CC - 0 CT 2497 [1762–3614] 17 TT 3859 [2963–7298] 28 0.3706 0.0122
 rs1872121 0.228 0.941 AA 1402 [750–1565] 4 AG 3041 [2307–5558] 13 GG 3826 [2853–7298] 28 0.4144 0.0047
 rs3745274 - 0.242 GG 2142 [1478–2569] 15 GT 3826 [3092–6473] 22 TT 8228 [6214–14178] 8 0.7242 <0.0001d
 rs10401737 0.592 0.264 CC 7198 [3911–11123] 12 CT 3118 [2569–5558] 26 TT 1762 [1478–2307] 7 −0.5913 <0.0001d
 rs2279343 0.957 0.231 AA 2225 [1565–2691] 16 AG 4000 [3092–6473] 21 GG 8228 [6214–14178] 8 0.7141 <0.0001d
 rs12721649 0.165 0.668 AA - 0 AG 2225 [1565–3379] 16 GG 4033 [2963–7298] 28 0.4461 0.0024
 rs7246456 0.957 0.231 CC 2142 [1478–2569] 15 CT 4000 [3092–6914] 23 TT 7738 [5714–14829] 7 0.7012 <0.0001d
 rs8192719 0.957 0.231 CC 2142 [1478–2569] 15 CT 4000 [3092–6914] 23 TT 7738 [5714–14829] 7 0.7012 <0.0001d
 rs36118214 0.242 - AA 1402 [750–1565] 4 AG 3037 [2142–5558] 14 GG 4000 [2892–7681] 27 0.4803  0.0008d
 rs10853744 0.956 0.236 GG 2142 [1478–2569] 15 GT 4033 [3092–6914] 22 TT 7738 [5714–14829] 7 0.7019 <0.0001d
 Composite
 516/983c 		EXT 1962 [1478–2435] 14 INT 3415 [3092–5558] 21 SLO 8228 [6473–13528] 10 0.7578 <0.0001d
a

The r2 measure of LD between each chromosome 19 polymorphism, rs3745274 (516G→T) and rs36118214 are shown.

b

Spearman rank correlation coefficient assessing monotonically increasing or decreasing trend by genotype as an ordered continuous variable. The signs (+ or −) for rho value are determined by assigning numbers to each base as follows: A = 1, C = 2, G = 3, T = 4. P value corresponding to the Spearman rank coefficient test. Only polymorphisms with rho >0.3 or < −0.3 are shown.

c

Composite CYP2B6 genotypes were as follows: extensive metabolizer, no variant allele at either position 516 or 983; intermediate metabolizer, a single variant allele at either position 516 or 983, but not both; slow metabolizer, two variant alleles (i.e. either 516 T/T, 983 C/C, or 516 G/T with 983 T/C).

d

These P values are significant after Bonferroni correction for multiple comparisons.